ABIO
Price:
$28.8
Market Cap:
$34.82M
ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorad...[Read more]
Industry
Biotechnology
IPO Date
1997-08-08
Stock Exchange
NASDAQ
Ticker
ABIO
According to ARCA biopharma, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 26.61. This represents a change of -28.10% compared to the average of 37.01 of the last 4 quarters.
The mean historical Current Ratio of ARCA biopharma, Inc. over the last ten years is 19.62. The current 26.61 Current Ratio has changed 13.46% with respect to the historical average. Over the past ten years (40 quarters), ABIO's Current Ratio was at its highest in in the December 2023 quarter at 59.01. The Current Ratio was at its lowest in in the December 2017 quarter at 5.94.
Average
19.62
Median
12.72
Minimum
5.94
Maximum
59.01
Discovering the peaks and valleys of ARCA biopharma, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 142.45%
Maximum Annual Current Ratio = 59.01
Minimum Annual Increase = -65.41%
Minimum Annual Current Ratio = 5.94
Year | Current Ratio | Change |
---|---|---|
2023 | 59.01 | 56.45% |
2022 | 37.72 | 142.45% |
2021 | 15.56 | 8.94% |
2020 | 14.28 | 55.94% |
2019 | 9.16 | 7.16% |
2018 | 8.55 | 43.84% |
2017 | 5.94 | -33.62% |
2016 | 8.95 | -65.41% |
2015 | 25.88 | 131.89% |
2014 | 11.16 | -0.97% |
The current Current Ratio of ARCA biopharma, Inc. (ABIO) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
37.43
5-year avg
27.15
10-year avg
19.62
ARCA biopharma, Inc.’s Current Ratio is greater than Aerovate Therapeutics, Inc. (8.78), greater than Adagene Inc. (2.50), greater than Acrivon Therapeutics, Inc. Common Stock (12.75), greater than Rezolute, Inc. (13.79), greater than AN2 Therapeutics, Inc. (9.75), greater than Indaptus Therapeutics, Inc. (3.42), greater than Tempest Therapeutics, Inc. (1.69), greater than Comera Life Sciences Holdings, Inc. (0.90), greater than Forte Biosciences, Inc. (2.06), greater than ZIVO Bioscience, Inc. (0.17), greater than RenovoRx, Inc. (5.40), greater than Pasithea Therapeutics Corp. (14.81), greater than Quoin Pharmaceuticals, Ltd. (3.02), greater than Sio Gene Therapies Inc. (5.52), greater than Magenta Therapeutics, Inc. (14.64), less than TRACON Pharmaceuticals, Inc. (0), greater than CytomX Therapeutics, Inc. (0.66), greater than Spero Therapeutics, Inc. (1.04), greater than Neoleukin Therapeutics, Inc. (2.68), greater than Instil Bio, Inc. (15.33), greater than NextCure, Inc. (12.90), greater than null (9.07),
Company | Current Ratio | Market cap |
---|---|---|
8.78 | $76.81M | |
2.50 | $97.11M | |
12.75 | $202.87M | |
13.79 | $284.50M | |
9.75 | $39.99M | |
3.42 | $10.20M | |
1.69 | $39.52M | |
0.90 | $9.22K | |
2.06 | $23.39M | |
0.17 | $74.08M | |
5.40 | $30.96M | |
14.81 | $3.93M | |
3.02 | $2.95M | |
5.52 | $0 | |
14.64 | $42.44M | |
0 | $107.51K | |
0.66 | $69.65M | |
1.04 | $63.24M | |
2.68 | $8.20M | |
15.33 | $170.65M | |
12.90 | $33.33M | |
9.07 | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like ARCA biopharma, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like ARCA biopharma, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is ARCA biopharma, Inc.'s Current Ratio?
How is the Current Ratio calculated for ARCA biopharma, Inc. (ABIO)?
What is the highest Current Ratio for ARCA biopharma, Inc. (ABIO)?
What is the 3-year average Current Ratio for ARCA biopharma, Inc. (ABIO)?
What is the 5-year average Current Ratio for ARCA biopharma, Inc. (ABIO)?
How does the current Current Ratio for ARCA biopharma, Inc. (ABIO) compare to its historical average?